Table 1.
Sample Baseline Characteristics by Disease Cohort
| Overall (n = 453) | FSGS (n = 148) | MCD (n = 139) | MN (n = 80) | Other (n = 86) | |
|---|---|---|---|---|---|
| Age, y | 32.9 (22.5) | 33.8 (21.8) | 20.1 (19.3) | 51.6 (14.1) | 34.8 (21.8) |
| <18 | 170 (37.5%) | 56 (37.8%) | 89 (64.0%) | 1 (1.3%) | 24 (27.9%) |
| Sex | |||||
| Female | 183 (40.4%) | 51 (34.5%) | 68 (48.9%) | 31 (38.8%) | 33 (38.4%) |
| Male | 270 (59.6%) | 97 (65.5%) | 71 (51.1%) | 49 (61.3%) | 53 (61.6%) |
| Race | |||||
| White | 253 (56.3%) | 74 (50.3%) | 74 (53.2%) | 60 (75.0%) | 45 (54.2%) |
| Black | 116 (25.8%) | 55 (37.4%) | 34 (24.5%) | 11 (13.8%) | 16 (19.3%) |
| Other | 80 (17.8%) | 18 (12.2%) | 31 (22.3%) | 9 (11.3%) | 22 (26.5%) |
| Hispanic | 90 (19.9%) | 32 (21.6%) | 26 (18.7%) | 14 (17.5%) | 18 (20.9%) |
| Baseline eGFR, mL/min/1.73 m2 | 84.8 (40.8) | 73.8 (32.7) | 106.1 (50.6) | 81.0 (28.0) | 73.0 (31.8) |
| eGFR ≤ 60 | 128 (28.3%) | 62 (41.9%) | 15 (10.8%) | 18 (22.5%) | 33 (38.4%) |
| eGFR of 60-120 | 269 (59.4%) | 74 (50.0%) | 93 (66.9%) | 55 (68.8%) | 47 (54.7%) |
| eGFR > 120 | 56 (12.4%) | 12 (8.1%) | 31 (22.3%) | 7 (8.8%) | 6 (7.0%) |
| Baseline UPCR, mg/mg | 2.2 [0.7-4.5] | 2.4 [0.9-4.4] | 0.9 [0.1-4.0] | 4.1 [2.7-7.6] | 1.4 [0.6-2.9] |
| UPCR 0-0.3 | 73 (16.6%) | 12 (8.3%) | 48 (36.6%) | 0 (0.0%) | 13 (15.1%) |
| UPCR 0.3-1.0 | 72 (16.3%) | 27 (18.8%) | 22 (16.8%) | 8 (10.0%) | 15 (17.4%) |
| UPCR 1.0-3.0 | 121 (27.4%) | 45 (31.3%) | 22 (16.8%) | 15 (18.8%) | 39 (45.3%) |
| UPCR > 3.0 | 175 (39.7%) | 60 (41.7%) | 39 (29.8%) | 57 (71.3%) | 19 (22.1%) |
| Baseline medication use (multiple possible) | |||||
| Steroids | 161 (35.5%) | 39 (26.4%) | 87 (62.6%) | 9 (11.3%) | 26 (30.2%) |
| RAASi | 212 (46.8%) | 75 (50.7%) | 37 (26.6%) | 50 (62.5%) | 50 (58.1%) |
| CNI | 41 (9.1%) | 11 (7.4%) | 21 (15.1%) | 4 (5.0%) | 5 (5.8%) |
| Diuretics | 151 (33.3%) | 42 (28.4%) | 41 (29.5%) | 45 (56.3%) | 23 (26.7%) |
| Days from biopsy to baseline | 19.0 [8.0-31.5] | 16.0 [8.0-27.0] | 17.0 [7.0-35.0] | 17.0 [10.5-27.0] | 22.0 [14.0-32.0] |
| Follow-up time, mo | 3.6 [2.1-4.6] | 4.1 [2.5-4.6] | 3.6 [2.1-4.5] | 4.0 [2.3-4.6] | 2.5 [1.8-3.6] |
| Pathology | |||||
| % Interstitial fibrosis | 5.0 [1.0-20.0] | 16.0 [3.0-27.0] | 1.0 [0.0-4.0] | 7.0 [4.0-12.0] | 21.0 [9.5-35.0] |
| % Tubular atrophy | 5.0 [0.0-16.0] | 13.0 [3.0-25.0] | 0.0 [0.0-2.0] | 6.0 [3.0-11.0] | 21.0 [8.0-34.5] |
| % Global sclerosis | 3.3 [0.0-17.9] | 9.0 [0.0-32.7] | 0.0 [0.0-3.6] | — | 4.9 [0.0-33.3] |
| Foot-process effacement | |||||
| 0%-10% | 16 (6.2%) | 4 (3.5%) | 12 (12.8%) | 0 (0%) | 0 (0%) |
| 11%-25% | 29 (11.2%) | 13 (11.3%) | 13 (13.8%) | 1 (2.3%) | 2 (28.6%) |
| 26%-50% | 29 (11.2%) | 18 (15.7%) | 10 (10.6%) | 0 (0%) | 1 (14.3%) |
| 51%-75% | 43 (16.5%) | 23 (20.0%) | 11 (11.7%) | 7 (15.9%) | 2 (28.6%) |
| 76%-100% | 143 (55.0%) | 57 (49.6%) | 48 (51.1%) | 36 (81.8%) | 2 (28.6%) |
Note: Values for categorical variables are given as percentages; values for continuous variables are given as mean (standard deviation) or median [interquartile range]. Missingness: race, <1%; ethnicity, <1%; baseline UPCR, <5%; interstitial fibrosis, tubular atrophy, 30.3%; % global sclerosis, 53.9%; foot-process effacement, 38.9%.
Abbreviations: CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; MCD, minimal change disease; MN, membranous nephropathy; RAASi, renin-angiotensin-aldosterone system inhibitor; UPCR, urinary protein-creatinine ratio.